34 results about "Drug dosages" patented technology

This application relates to a drug dosage monitoring device and a drug delivery system. The drug monitoring device includes: a drug reservoir with a drug storage chamber; a piston located within the drug storage chamber; a fixed electrode located outside the second end of the drug reservoir; multiple electrode plates located between the fixed electrode and the second end of the drug reservoir, with the multiple electrode plates and the fixed electrode arranged at intervals; a wire clamping device located on the side of the piston away from the first end of the drug reservoir; and a wire in contact with both the fixed electrode and the wire clamping device. The wire contacts at least one of the multiple electrode plates when the piston moves to different positions within the drug reservoir. The drug dosage monitoring device of this application can determine the position of the piston by detecting the continuity between the fixed electrode and each electrode plate. Based on the position of the piston, the amount of drug output from the drug reservoir in one piston movement and the remaining amount of drug in the drug reservoir can be determined.

A pharmaceutical composition, an organ preservation solution, and their applications are disclosed, wherein the pharmaceutical composition comprises cedutinib and edaravone. The mass ratio of cedutinib to edaravone is 1:0.0001-10000. The pharmaceutical composition of the present invention exhibits good cell protection effects, and cedutinib and edaravone demonstrate a synergistic effect, contributing to excellent therapeutic efficacy, reducing drug dosage, and improving clinical drug safety.

The present application relates to a kind of fungicide composition and its application, including active ingredient A and active ingredient B, the active ingredient A is the compound shown in formula (I), and active ingredient B is acypetins.The mass ratio of active ingredient A and active ingredient B is 1:36~34:1.The fungicide composition of the present application or its preparation can enhance efficacy, reduce drug dosage, while improving control effect and delaying the development of drug resistance.

This invention application provides compositions containing red yeast rice pigment and their applications, compositions with α-glucosidase inhibitory activity and their applications, and further, their application in α-glucosidase inhibitors, belonging to the technical field of natural active compounds inhibiting α-glucosidase. The compositions of this invention comprise one or both of red yeast rice pigment and red yeast rice pigment: wherein the molar ratio of acarbose to red yeast rice pigment is 400:400-600:300; the molar ratio of acarbose to red yeast rice pigment is 400:200-600:150; and the molar ratio of red yeast rice pigment to red yeast rice pigment is 150:400-200:300. The compositions involved in this invention have a significant synergistic inhibitory effect on α-glucosidase, superior to using the above compounds alone, and can achieve reduced drug dosage and reduced drug side effects.

The present application relates to a kind of fungicide composition and its application, including active ingredient A and active ingredient B, the active ingredient A is the compound shown in formula (I), and active ingredient B is prochloraz.The mass ratio of active ingredient A and active ingredient B is 1:36~34:1.The fungicide composition of the present application or its preparation can enhance efficacy, reduce drug dosage, while it can improve the prevention and treatment effect and delay the development of drug resistance.

This utility model relates to the field of medical device manufacturing technology and discloses a medical patch coating and laminating machine, including a base plate. A housing is fixedly connected to the upper surface of the base plate, and a first motor is fixedly connected to the outer wall of the housing. A worm gear is fixedly installed at the output end of the first motor. A worm wheel is meshed with the tooth end of the worm gear, and a lead screw is internally threaded onto the worm wheel. An application block is fixedly connected to the lower surface of the lead screw, and the outer wall of the application block is slidably connected to the inside of a support. A feeding assembly is provided on the upper surface of the support, and the feeding assembly is used to control the feeding of the medicine. In this utility model, when the worm wheel rotates, the application block slides upward into the inside of the support through the internally threaded lead screw, coating the fabric moving below. The coating thickness can be adjusted to achieve precise control of the drug dosage, adapting to products of various thicknesses and facilitating the efficient production of diverse medical patches.

The application discloses application of a swertianol derivative in preparation of a glioma treatment drug and belongs to the technical field of medicines. The application finds that the compound has significant inhibitory activity on SF126, T98G, A172, U-87 MG, U251 and various glioma cell lines, and the activity is better than that of temozolomide, a commonly used clinical anti-glioma drug, and the compound has lower toxicity to normal brain cells. The application further provides a preparation method of the compound and a pharmaceutical composition containing the compound, and the pharmaceutical composition can be prepared into injection, tablets and various dosage forms. The application provides a new effective drug selection for the treatment of glioma, has a mature preparation process, various drug dosage forms and a wide clinical application prospect.

Biomarkers for treatment response and other outcomes in the treatment of lesions, such as cancerous tumors, are derived from routine clinical medical images, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans, using radiomic machine learning techniques. The biomarkers are based, at least in part, on phenotypes derived from vessel morphology features descriptive of vasculature associated with a lesion shown in the medical images and may also include other radiomic and pathomic types of features. The biomarkers and phenotypes may be used at multiple points in the treatment process, and treatment decisions may be based on changes in radiomic features or phenotypes longitudinally through the course of treatment. The biomarkers and phenotypes may also be used in clinical trials, to establish trial parameters, patient enrollment, drug dosage, and other trial parameters.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

The present application relates to the technical field of biological medicine, in particular to a kind of nano-molecular probe with targeting and its preparation method and application.The plasmid of immune checkpoint corresponding receptor of stable expression tumor surface negative regulation molecule is synthesized in the present application, which is prepared into targeted nano-molecular probe with cell membrane nanocapsule of enhancing T cell activity ligand and being marked with fluorescence, and melanin nanosphere of simultaneously loading therapeutic drug.The targeted nano-molecular probe provided in the present application can be long-circulated in vivo, reduce the dosage and administration frequency of chemotherapeutic drug.It also has the advantages of improving the drug resistance of tumor site to therapeutic drug, targeting tumor DNA damage and significantly enhancing the infiltration and activation of immune cells in tumor site.

1. Name of the product in this design: Icons for a graphical user interface of a mobile phone for disease and medication management. 2. Purpose of this design: To provide an icon for displaying and running a graphical user interface for a mobile phone, which allows the user to start a timer for setting drug dosage. 3. The key design features of this product are found in the graphical user interface. 4. The image or photograph that best illustrates the design's key points: the front view. 5. Human-computer interaction method of graphical user interface: Users click or press the button in the icon to start the timer for drug dosage setting. 6. Other matters requiring explanation: This design is a partial design; the dashed lines show the display screen and graphical user interface portion, which do not constitute part of the design for which protection is claimed.

A method of preparing liquid medication doses using an automated dosing device may include securing a vial within a vial holder. The vial includes a liquid medicament. An empty syringe is secured within a syringe holder with a plunger of the syringe being secured by a plunger gripper and a luer lock of the syringe within a luer lock gripper. The syringe holder and the vial holder are moved closer together to insert a needle of the syringe through a septum of the vial while longitudinal axes of the syringe and the vial are at a downward angle and while the vial holder is lower than the syringe holder. The syringe holder and the vial holder are rotated to vertically align the longitudinal axes with the vial holder above the syringe holder. The plunger gripper is pulled away from the luer lock gripper to transfer liquid medicament into the syringe.

This invention discloses an antimicrobial peptide RY-10 and its application in the preparation of antimicrobial drugs, belonging to the field of biomedical technology. The amino acid sequence of the antimicrobial peptide RY-10 is shown in SEQ ID NO.2. The antimicrobial peptide RY-10 provided by this invention has a highly efficient killing ability against a variety of Gram-negative / positive bacteria, effectively retaining antimicrobial activity while significantly reducing cytotoxicity. Simultaneously, this antimicrobial peptide RY-10 can also produce synergistic antimicrobial effects with various antibiotics, showing significant application value in improving efficacy, overcoming antibiotic resistance, reducing drug dosage, delaying the development of drug resistance, and addressing complex infections. This invention provides a highly promising candidate material resource for the development of highly effective and low-toxicity antimicrobial drugs, and also provides an efficient, safe, and sustainable solution for developing novel combination therapies and addressing the global drug resistance crisis, possessing significant clinical application value and industrialization potential.

The application discloses a kind of based on nanometer friction power generation nematode high-throughput drug screening method and system, including nanometer friction power generator and microfluidic chip;The nanometer friction power generator is combined above the microcolumn array in the microfluidic chip correspondingly.Combination of the nanometer friction power generator and microfluidic chip, compared with prior art, realizes miniaturization, low cost, high efficiency collection method, throws away the high observation collection equipment.In addition, the drug dosage of drug screening experiment is controlled within 100 μL, greatly reduce the drug dosage consumed.

This utility model discloses a dosing device for precise control of drug dosage, including a solid storage tank and a liquid storage tank. The solid storage tank is equipped with a sealing cover, and a stirring motor is mounted on the sealing cover. A conveying pipe is located at the bottom of the solid storage tank, and a flow meter and a vibration motor are mounted on the conveying pipe. A stirring rod is located below the sealing cover, and a locking component and a connecting frame are mounted on the stirring rod. The output end of the stirring motor has a connection port and a positioning block with a locking hole. A cavity is formed between the inner and outer walls of the conveying pipe. This utility model, through the inclusion of a locking component, connecting frame, connection port, positioning block, locking hole, vibration motor, cavity, and spring, allows for easy disassembly of the stirring rod after installation, facilitating subsequent cleaning and replacement of the stirring rod. Furthermore, this structure prevents solid drugs from accumulating and clogging the conveying pipe, thus ensuring smooth delivery of the solid drugs.

The application provides application of thiofungchinol and matrine in preparation of preparations for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of medicines.The application effectively overcomes the defects of limited curative effect and large toxic and side effects of the radiation-induced lung injury prevention and treatment drugs in the prior art, and the thiofungchinol and the matrine can play a synergistic effect when being used in combination, so that the prevention and treatment effect on the radiation-induced lung injury is significantly improved, the single drug dosage is reduced, the toxic and side effects are reduced, and a new scheme is provided for clinical intervention of RILI.

This invention discloses a porcine circovirus vaccine filling device, relating to the field of vaccine filling technology. The device includes a filling assembly comprising a base, a support frame on top of the base, the support frame being L-shaped, a servo motor at the top of the support frame, and a connecting frame fixedly mounted on the bottom telescopic end of the servo motor through the support frame. The connecting frame has several sets of mounting holes arranged sequentially, through which connecting pipes are installed. This invention, by setting up the filling assembly, can effectively buffer the filling process. The sieve plate provides effective buffering and defoaming, solving the problem of air bubbles easily generated during filling in existing devices. It avoids the problem of large differences in drug dosage due to air bubbles, ensuring the product complies with veterinary pharmacopoeia regulations. Simultaneously, it prevents oxygen in the air bubbles from accelerating the oxidative denaturation of vaccine antigen proteins, ensuring the drug's efficacy and preventing immunization failure.

The present invention relates to the technical field of medicine, and relates in particular to a molecule having a targeting function. The molecule having a targeting function can specifically deliver a drug to a specific cell, which facilitates precise programming of a specific cell in the body, a therapeutic effect of the drug is produced, and consequently drug dosage and side effects are greatly reduced, and the effect of precise treatment to cells in the body is achieved.

A medical patch, a medical system, and a method of drug delivery are provided. The medical patch includes: a first film including a first surface and a second surface opposite to the first surface, wherein a plurality of medical needle structures are disposed on the first surface; a second film disposed facing the second surface and including a conductive circuit structure; and a flexible film disposed between the first film and the second film and capable of deformation. The plurality of medical needle structures include: a storage section for storing a drug; and a drug dosage sensing section for sensing information related to the amount of drug remaining in the storage section. The conductive circuit structure includes a communication tag capable of wireless communication.

The utility model discloses a kind of be applied to the comminuting device of crude drug, including base, control mechanism is installed in the upper portion of base, the control mechanism is connected with comminuting mechanism;Motor drive screw feeder feeds and comminutes to the comminuting mechanism.The control mechanism includes the control box being installed in the upper portion of base, switch is arranged on the control box, for starting or closing the comminuting mechanism;It also includes external frequency converter and control system, the frequency converter and the control system are connected with the comminuting mechanism and the control box by communication module or cable.The product granularity of device after grinding is finer, smallest can make material evenly reach 200 microns, can improve drug dissolution rate and bioavailability, enhance preparation uniformity and stability, expand drug dosage form and application range, can satisfy the demand of different customer groups, increase product added value and its sales volume.

The application belongs to the field of medicine, and particularly relates to a nanomaterial for treating uveal melanoma, a preparation method, application and medicine of the nanomaterial, wherein the nanomaterial for treating uveal melanoma comprises a core and a hyaluronic acid coating layer covering the core; the core comprises a zinc / copper bimetallic organic framework and a compound of formula 1, wherein formula 1 is. In view of the pathogenesis, characteristics and treatment problems of ophthalmology UM, the application provides a brand-new nanomaterial which is based on the combined synergy of zinc / copper bimetallic organic framework, compound of formula 1 and HA component and structure, so as to realize synergy, to inhibit cancer cells of uveal melanoma in a high-selectivity manner based on multi-mechanism combined synergy, to be able to exert excellent treatment activity at a low drug dosage, and to be able to effectively inhibit metastasis. In addition, the nanomaterial has excellent biological safety.

The application relates to a MYH2-FIGN interaction blocking amino acid compound and an application thereof, and relates to the fields of polypeptide drugs and tumor prevention and treatment. The MYH2-FIGN interaction blocking amino acid compound is an amino acid sequence as shown in SEQ ID NO:1 or SEQ ID NO:3 or a polypeptide derivative thereof. The application further discloses a pharmaceutical composition containing the MYH2-FIGN interaction blocking amino acid compound and a pharmaceutically acceptable carrier. The application first designs a polypeptide drug targeting the MYH2-FIGN interaction interface, and compared with traditional small molecules, the polypeptide drug has specificity for MYH2-FIGN interaction inhibition, and through fusion of an iRGD peptide, not only is the polypeptide cell penetration problem solved, but also the polypeptide drug is endowed with tumor targeting, the bioavailability of the drug is improved, and the systemic toxicity is reduced. The polypeptide drug can adopt various drug dosage forms, and the preparation process is simple.

This invention relates to the field of chemical pharmaceutical formulation manufacturing technology, and discloses a shikonin composition for inhibiting non-specific inflammation of the reproductive system, comprising: nanomicelles formed by encapsulating shikonin with tocopherol polyethylene glycol 1000 succinate, phenylboronic acid-modified sodium hyaluronate, and a lactic acid buffer system. The phenylboronic acid-modified sodium hyaluronate constructs a gel anchoring layer by complexing the phenylboronic acid groups with the ortho-dihydroxy structure on the action surface. This invention utilizes hydrogen peroxide to induce an oxidative deboronization reaction at the inflammatory lesion, causing an in-situ phase transition from a gel state to a sol state in the gel anchoring layer, eliminating drug diffusion resistance, and resolving the mismatch between mucosal clearance and drug release rate. The composition enhances the chemical stability of shikonin while achieving feedback regulation of drug dosage and inflammation degree, effectively repairing the mucosal barrier and maintaining local microecological balance.

The present application relates to the technical field of medicine, and provides a valerian microemulsion temperature-sensitive gel, a preparation method and application thereof.The valerian microemulsion temperature-sensitive gel is composed of a drug valerian extract, an oil phase, a surfactant, a cosurfactant, poloxamer, carboxymethyl chitosan and water.The prepared valerian microemulsion temperature-sensitive gel is in a liquid state at normal temperature, and is converted from the liquid state to a gel state when contacting the skin or mucosa temperature, has almost no irritation to the skin, is safe to use, has a large transdermal permeation amount, a high transdermal permeation rate, a long retention time on the skin surface or mucosa, and has a good sustained-release effect.The preparation method is simple, low in cost, convenient and safe to use, and can effectively promote skin wound healing.The present application provides a new drug dosage form for treating skin wounds or mucosa administration.

The present invention relates to a pharmaceutical composition comprising a biologically active agent and one or more carbon 13 labelled taggant as defined herein. The present invention further relates to a method of determining adherence to, or unauthorised use of, a pharmaceutical dosage regimen comprising use of said pharmaceutical composition, a system for identifying use of a biologically active agent, and the use of a taggant as defined herein for preparation of said pharmaceutical composition. In one aspect, the taggant is a compound of formula (1): or a pharmaceutically acceptable salt thereof, and wherein the compound of formula (1) contains at least one carbon 13 atom.

This invention relates to the field of intelligent rehabilitation nursing technology, specifically to an interactive management method and system for rehabilitation nursing that integrates the Internet of Things (IoT) and AI. The method includes the following steps: collecting heart rate, blood oxygen, and body temperature data from a wearable terminal and aligning them with the time; combining this with body mass index (BMI) and previous medical records; determining drug dosage and exercise metabolic equivalent based on risk-matching nursing rules; and adjusting parameters and updating the intervention parameter set based on feedback scores. In this invention, by accurately aligning timestamps and collecting multidimensional physiological data, the time synchronization problem in traditional methods is avoided. Kalman filtering improves the accuracy and anti-interference ability of data fusion. Combined with health risk analysis, personalized rehabilitation intervention plans are achieved. Bayesian networks, through comprehensive evaluation of physiological data, BMI, and historical medical records, accurately determine drug dosage and exercise metabolic equivalent, providing decision support for individualized treatment. A dynamic adjustment mechanism ensures real-time updates of nursing parameters, improving rehabilitation effectiveness and nursing quality.

This invention relates to the field of biomedical dressings, specifically disclosing an exosome-loaded tanshinone hypertrophic scar dressing and its preparation method. The dressing comprises an exosome-tanshinone complex, methacrylamide gelatin, oxidized dextran, and a photoinitiator. The key to its preparation lies in: first, using DSPE-PEG-Maleimide as a bridge, covalently coupling the RGD targeting peptide to the exosome membrane via a Michael addition reaction to construct an active targeting carrier; then, efficiently loading tanshinone IIA using electroporation to form a complex; finally, mixing the complex with a gel precursor and cross-linking it under ultraviolet light. This invention solves the problem of easy detachment of the targeting ligand through chemical coupling, and utilizes a dual-network hydrogel to achieve responsive drug release to the MMP-2 enzyme in the scar microenvironment, thereby improving the local anti-fibrotic efficacy while reducing the single-drug dosage and toxic side effects.

The application discloses an antibacterial peptide RK-8 and application thereof in preparation of antibacterial drugs, and belongs to the technical field of biological medicine. The amino acid sequence of the antibacterial peptide RK-8 is shown as SEQ ID NO. 2. The antibacterial peptide RK-8 provided by the application has high killing capacity on various gram-negative / positive bacteria, effectively retains antibacterial activity, greatly reduces cytotoxicity, and improves treatment effect. Meanwhile, the antibacterial peptide RK-8 can also produce synergistic antibacterial effect with various antibiotics, has significant application value in improving curative effect, overcoming antibiotic resistance, reducing drug dosage, delaying drug resistance, and coping with complex infections. The application provides a promising candidate substance resource for developing high-efficiency and low-toxicity antibacterial drugs, and provides an efficient, safe and sustainable solution for developing a new combined therapy and coping with the global drug resistance crisis, and has important clinical application value and industrialization potential.